The vast majority of these subjects require long-term oral anticoagulation for prevention of thromboembolism with vitamin K antagonists (VKA) or nonvitamin K oral anticoagulants (NOAC) such as apixaban, a direct factor Xa (FXa) inhibitor.[1–5] Apixaban has been shown to be superior to VKA regarding thromboembolic events and bleeding complications in patients with AF.[6]. Here, F10 is linked to Thromboembolism.